The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning for women using weight-loss injections, such as Mounjaro and Wegovy, emphasizing the necessity of effective contraception during treatment. This advisory arises from concerns regarding the potential effects of these medications on unborn babies, as well as the possibility that these injections may reduce the effectiveness of oral contraceptives in women who are overweight or obese.
The MHRA has highlighted that gastrointestinal side effects from these medications, including vomiting and diarrhea, could hinder the absorption of contraceptives. Women are advised to use contraception while on these medications and for a defined period afterward—two months for Wegovy and Ozempic, and one month for Mounjaro. Additionally, those using Mounjaro should consider alternative contraceptive methods or use condoms for four weeks after starting the medication.
Reports have indicated that some women may not be receiving adequate information about the risks associated with these drugs. Natasha Major, a 26-year-old woman who became unexpectedly pregnant while using Mounjaro, exemplifies this issue. She reported having used the contraceptive pill, yet was surprised to learn of her pregnancy shortly after starting the medication.
The MHRA has received approximately 40 reports of unintended pregnancies linked to these weight-loss drugs, underscoring the need for better communication about their use. Experts recommend that women consult healthcare professionals for guidance on contraception and the potential implications of these medications on pregnancy. Furthermore, the British Pregnancy Advisory Service has noted the various challenges women face in accessing their preferred contraceptive methods, advocating for improved healthcare access and planning.